Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ASCO Highlights
Meeting Highlights
ASCO Highlights
Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma
Read More
Meeting Highlights
ASCO Highlights
ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC
Read More
Meeting Highlights
ASCO Highlights
Cediranib Combined with Olaparib Is Active in Patients with Platinum-Pretreated SCLC
Read More
Meeting Highlights
ASCO Highlights
Nationwide Genomic Screening Network Can Be Effective in Identifying Rare Targetable Genetic Alterations
Read More
Meeting Highlights
ASCO Highlights
Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC
Read More
Meeting Highlights
ASCO Highlights
Retrospective Data Suggest Role for Immunotherapy in Patients with Large-Cell Neuroendocrine Carcinoma
Read More
Meeting Highlights
ASCO Highlights
3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227
Read More
Meeting Highlights
ASCO Highlights
CheckMate-9LA Evaluates Addition of Chemotherapy to NIVO + IPI in First-Line Advanced NSCLC
Read More
Meeting Highlights
ASCO Highlights
Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
Read More
Meeting Highlights
ASCO Highlights
Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR
Read More
1
2
3
4
5
Page 4 of 5
Results 31 - 40 of 42